Our new study by @JieunOh9@ericsongg@MiyuMoriyama et al shows that immune priming via intranasal route provides superior protection against heterologous respiratory virus challenge. The key is in inducing local secretory IgA with broader coverage. (1/)
Mucosal surface epithelium expresses polymeric Ig receptor (pIgR), which transports dimeric IgA + J-chain secreted from plasma cells within the tissue, across to the luminal side. IgA dimer + J-Chain + part of pIgR is released as ‘secretory IgA’. Figure by @BioRender. (2/)
The secretory IgA can bind viruses, bacteria, toxin in the lumen of intestine and neutralize them. Advantages of secretory IgA is the extended longevity as well as having 4 Fab instead of 2 Fab (monomeric IgA) to bind to the antigen. Secretory IgA is well studied in the gut. (3/)
What about sIgA in the lung? Here, we show that only nasal, but not parenteral, priming induces secretory IgA in the lung. Similar circulating Abs are induced by both routes. Note we used ~30 PFU x1 for nasal and 4 million PFU x5 for i.p. priming. sIgA induction via👃🏼>>💉 (4/)
When you look inside the lungs of nasal vs. parenteral primed mice 5 weeks later, nasal primed mice contain tons of plasma cells secreting IgA beneath the epithelium, and IgA is bathing the lumen of the lung 😲 (5/)
These IgA secreting cells at 5 weeks post prime are mostly tissue-resident cells (meaning they sit within the lung and do not move around). (6/)
What is the source of lung IgA? Is it circulating antibodies or locally produced? @JieunOh9 tested this by creating parabiotic mice. She found that most of the lung IgA is coming from the local tissue-resident IgA secreting cells. (7/)
@Ericsongg analyzed the transcriptional profiles in lymph node and lung B cells. He found IgA secreting cells in the lung were mostly plasma cell, plasmablasts and memory B cells, & were CXCR3+, a chemokine receptor we found earlier for HSV memory B. (8/) pubmed.ncbi.nlm.nih.gov/31189952/
Knocking out CXCR3 in B cells led to less IgA secreting cells in the lung, and less IgA secreted into the lung. Thus, B cell intrinsic CXCR3 is necessary for establishment of IgA secreting cells in the lung. (9/)
A key finding in our study is that intranasal but not systemic immunization led to cross-protective immunity against heterologous influenza virus in the absence of T cells. Only intranasal priming led to the production of cross-reactive IgA in the lung secretion 👇🏽 (10/)
As part of the effort to create universal flu vaccine, @florian_krammer’s group developed a recombinant neuraminidase (rNA) vaccine. Adjuvanted rNA vaccine provides robust protection to heterologous influenza viruses when nasally administered. (11/)
With @Shirin_Strohm & @florian_krammer, we tested whether this rNA vaccine also rely on local IgA. In immunized mice, only nasal route induced IgA+ B-resident memory cells and protected against heterologous challenge in the absence of T cells. Via @MiyuMoriyama 💪🏼 (12/)
These results indicate that nasal vaccines induce IgA and promote better cross-protective immunity against viral variants, and suggest its utility in combating COVID-19 variants of concern. A great write up by Bill Hathaway. (13/)
Highlighting all the authors that made this study possible, incl. Patrick Wong, Sophia Zhang, @RuoyiJiang@skleinstein. We started this work four years ago when @JieunOh9 was still a postdoc in the lab. Now she runs her own lab at @kaistpr 💪🏼 Thanks for reading till the end.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Despite a number of studies, whether HIV infected individuals are at higher risk of COVID-19 diagnosis, hospitalization, and mortality remains unclear due to variable results found in the population studies, cohort studies, and case series. (2/)
People with chronic HIV infection have distinct immune profiles, such as reduced IFN-I, chronic inflammation, CD4 ⬇️, CD8 exhaustion, poor B cell responses, which impair immune defense against SARS-CoV-2. (Beautiful figure 🎨 by @YYexin) (3/)
A preprint by Michael Simon et al @ArcadiaHealthIT shows that COVID vaccines given before or AFTER infection can reduce incidence of #longCOVID, based on a retrospective analysis of the health record of 240,648 COVID-19-infected people. 🧵(1/)
People who received at least one dose of any of the 3 COVID vaccines in the US prior to COVID diagnosis were 8.8x less likely to report >1 long COVID symptoms between 12-20 weeks after diagnosis. (2/)
This reduction in LC risk appears high, given other studies that found 50% reduction or no reduction by prior vaccination in LC among breakthrough infection. Perhaps this depends on how one measures and defines long covid. (3/)
Our latest study is about an immunocompromised patient with persistent COVID ➡️ treated with remdesivir but developed resistant mutation ➡️ was then cured by monoclonal Ab cocktail. Study by @gandhisk@sneakyvirus1@epidememeology@marioph13 et al. (1/)
This patient received a course of rituximab (B cell depleting Ab) and bendamustine (chemo agent) for the treatment of Stage IV Non-Hodgkin's lymphoma. As a result, patient had extremely low number of T cells and low lymphocyte counts overall. Analysis by @peowenlu (2/)
So when she was infected with SARS-CoV-2, she was unable to clear the virus for over 150 days. She developed persistent fever, anosmia and ground glass opacities in her lungs. Her viral load stayed high until the remdesivir treatment. (3/)
For description of this study, please see my thread from when we first posted the paper in @medrxivpreprint in March 👇🏽 One of the deepest immune profiling that captures reinfection in a longitudinal manner. (2/)
In a nutshell, this transplant patient had, prior to reinfection;
• Huge levels of circulating innate and adaptive cytokines (chronic inflammation)
• Very few naive lymphocytes & dominant exhausted T cells
• Elicited poor and transient neutralizing Ab responses
(3/)
1) mRNA vaccines (2 shots) induce robust antibodies & T cells to SARS-CoV-2 2) certain mutations in VOC ⬆️ Ab escape 3) prior infection + 2 mRNA shots produce very high neutralizing Ab against most VOC 🦠(1/)
An important new study looks at how COVID vaccines impacts symptoms in #LongCovid patients. @thitran3’s team used data from ComPaRe long COVID cohort to emulate a target trial (1:1 matched vax:unvax) measuring outcome at 120 days after baseline. (1/)
The study found that the rate of complete remission from long COVID symptoms doubled in vaccinated patients compared to unvaccinated long COVID patients. Wow, vaccines appear to be helping long haulers with recovery 👏🏼 (2/)
In addition, disease impact of long covid on patients’ lives were significantly reduced (symptoms improved) in vax group (long COVID IT score of 24.3) compared to unvax group (IT score of 27.6). (3/)